Skip to main content
The Markets by Proactive
Go to Proactive UK
Proactive UK has moved. Proactive’s coverage of London’s small caps continues on proactiveinvestors.com Go there →
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Coverage of London’s small caps continues on proactiveinvestors.com
Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK

Pharma & Biotech

Futura Medical ED drug roll continues apace

The roll-out of Futura Medical PLC (AIM:FUM, OTC:FAMDF)'s breakthrough erectile dysfunction (ED) gel continues apace with sales starting in the company's first market in the Middle East.

Eroxon will now be for sale online through the BinSina Pharmacy in the United Arab Emirates, adding to the sales momentum coming from the UK and Belgium.

In a recent Proactive interview, Futura CEO James Barder said of the commercial impetus: "The early signs are very encouraging; we've achieved around a 20% market share in the segment of clinically proven erectile dysfunction treatments."

Eroxon has been developed as a fast-onset alternative for men who struggle with the side-effects of traditional blue pill treatments. The product is the only erectile dysfunction treatment approved by the US Food & Drug Administration to be sold over the counter.

Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK